SYDNEY, April 29,
2022 /PRNewswire/ -- Kazia Therapeutics Limited
(NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development
company, today announced that final data from its phase II study of
paxalisib in patients with newly diagnosed glioblastoma will be the
subject of a poster presentation at the upcoming Annual Meeting of
the American Society for Clinical Oncology (ASCO).
The ASCO Annual Meeting will take place virtually and in person
from 3-7 June 2022 and will be held
in Chicago, IL.
Abstracts from the meeting are expected to be released from
5pm, ET, on 26
May 2022, and the poster will be made available by ASCO and
via the Kazia website shortly after presentation.
POSTER PRESENTATION
Title: Paxalisib in patients with newly diagnosed
glioblastoma with unmethylated MGMT promoter status: Final phase 2
study results.
Date and Time: Sunday, 5 June
2022 – 8am – 11am, CDT
Session: Central Nervous System Tumors
Abstract ID: 2047
About Kazia Therapeutics Limited
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) is an
oncology-focused drug development company, based in Sydney, Australia.
Our lead program is paxalisib, a brain-penetrant inhibitor of
the PI3K / Akt / mTOR pathway, which is being developed to treat
glioblastoma, the most common and most aggressive form of primary
brain cancer in adults. Licensed from Genentech in late 2016,
paxalisib commenced recruitment to GBM AGILE, a pivotal study in
glioblastoma, in January 2021. Seven
additional studies are active in various forms of brain cancer.
Paxalisib was granted Orphan Drug Designation for glioblastoma by
the US FDA in February 2018, and Fast
Track Designation for glioblastoma by the US FDA in August 2020. In addition, paxalisib was granted
Rare Pediatric Disease Designation and Orphan Designation by the US
FDA for DIPG in August 2020.
Kazia is also developing EVT801, a small-molecule inhibitor of
VEGFR3, which was licensed from Evotec SE in April 2021. Preclinical data has shown EVT801 to
be active against a broad range of tumour types and has provided
compelling evidence of synergy with immuno-oncology agents. A phase
I study commenced recruitment in November
2021.
For more information, please visit www.kaziatherapeutics.com or
follow us on Twitter @KaziaTx.
This document was authorized for release to the ASX by
James Garner, Chief Executive
Officer, Managing Director.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/kazia-to-present-final-data-from-paxalisib-phase-ii-study-in-glioblastoma-at-asco-301535395.html
SOURCE Kazia Therapeutics Limited